Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Hereditary cancer | September 30, 2022
Check out a recent publication from Capone et al from the University of Florence!
In this study, the Devyser BRCA test was used to analyze 227 patient DNA samples. They concluded that 100% of the expected SNVS and CNVS were detected and that the single-tube PCR-based library preparation format of the kit offers a decrease in processing time as well as a reduced risk of cross-contamination.
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More